Unraveling the Future | Trends and Projections in Hormone-Sensitive Advanced Prostate Cancer Treatment Market

The global Hormone-Sensitive Advanced Prostate Cancer Treatment Market Revenue is expected to be worth US$ 12.44 billion by 2023. According to Future Market Insights, the market will grow at a 7.2% CAGR through 2033, with a market size of US$ 24.94 billion.

The major providers' principal goal is to integrate science into breakthrough oncology drugs for cancer sufferers globally, where they pledge to potentially provide new hope driving the mission and allowing accessibility through their cancer treatments.

The market for prostate cancer treatments is being stifled by recurrent/non-responsive prostate cancer. This is because recurrent/non-responsive prostate cancer cells cause cancer to recur or spread after first treatment. Despite targeted treatment, recurrence occurs in 50% to 95% of men with high-risk prostate cancer in the United States, according to the American Society of Clinical Oncology (ASCO).

The FDA oversees the market for prostate cancer treatments in the United States. The FDA is in charge of drug approval and creating guidelines for prostate cancer treatment. This was the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and there will be more in the future. As a result, the regulatory framework governing prostate cancer treatments will encourage additional drug companies to enter the market.

Major Players

  • Novartis Pharmaceuticals
  • Merc & Co., Inc.
  • Bristol-Myers
  • Dendreon Corporation
  • GlaxoSmithKline plc.
  • Ferring International Center S.A.
  • Roche Group
  • Celgen Corporation
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd

Get More Details@ https://www.futuremarketinsights.com/reports/hormone-sensitive-advanced-prostate-cancer-market

Key Segments Profiled in the Hormone Sensitive Advanced Prostate Cancer Treatment Market Report

By Treatment:

  • Androgen Ablation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Cryotherapy

By End User:

  • Hospitals
  • Clinics
  • Cancer Rehabilitation Centers

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more